Fuad El-Hibri and Healthcare Reform

Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University. The 6^th annual healthcare conference was held on April 9, 2010 in New Haven, CT. The conference topic was “Re-Forming Healthcare: Excellence in a Transforming System” and brought together professionals, academics, and students to engage in an instructive conversation about current healthcare issues.

Fuad El-Hibri

The conference addressed the challenges key stakeholders will face in a changing healthcare system and offered information on how to foster continued excellence. Emergent Biosolutions, LLC, led by CEO and Yale School of Management alumnus, Fuad El-Hibri, co-sponsored the conference. For more information, please see http://www.yalehealthcare.com/advisory.php.

Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly

Emergent BioSolutions’ senior management team, headed by Fuad El-Hibri, chairman and chief executive officer and Daniel J. Abdun-Nabi, president and chief operating officer, are hosting “Bioterrorism Prevention, Preparedness and Response,” a forum uniquely organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA). The one-day event is an interactive discussion related to biopreparedness strategies and best practices such as funding, development, and manufacture of biodefense medical countermeasures, creation of strategic stockpiles, and cooperation within the international community.

“Strengthening the Biological Weapons Convention and international cooperation in biodefense are of paramount importance. This forum organized by Emergent is extremely valuable in helping us, as national legislators, to obtain more information on biopreparedness and to promote the idea of strengthening national biodefense capabilities using the best practices and expertise developed by our Allies,” said Canadian Senator Pierre Claude Nolin, NATO PA Treasurer and Vice Chairman of the NATO PA Science and Technology Committee. “We are firm believers in international mechanisms to address bioterrorism challenges.”

The forum is to provide an overview of the United States’ approach to bioterrorism prevention, the role of the Department of Defense and the importance of coordination of international efforts. Featured speakers include: Congressman Mike Rogers (R-MI), Dr. Robert P. Kadlec, Director of PRTM Biodefense and Public Health Practice, Jim Saxton, former Member of the U.S. House of Representatives, and Dr. Tevi Troy, Senior Visiting Fellow at the Hudson Institute and former Deputy Director of the U.S. Department of Health and Human Services. The visiting delegation, led by NATO Officers of the Science and Technology Committee, is composed of parliamentarians from representative NATO nations including Canada, the Czech Republic, France, and Portugal. The forum is taking place in Washington, D.C.

Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of MarylandEmergent BioSolutions Recognized as Biotechnology Firm o

ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the state.

“It is an honor to represent Emergent BioSolutions, a company composed of talented and hardworking individuals committed to the corporate mission of protecting life,” said Fuad El-Hibri, chairman and chief executive officer, who received the award on behalf of the company.

Fuad El-Hibri Accepts the 2010 Tech Council of Maryland Biotechnology Firm of the Year Award

For 22 years, TCM has recognized companies that have helped establish Maryland’s thriving technology community. This year’s theme “Building Something Great Together” focuses on the tremendous growth and future outlook for the technology community.

“The theme, ‘Building Something Great Together,’ is meaningful because Emergent’s success is built on teamwork and collaboration,” Mr. El-Hibri continued. “It also acknowledges the role that businesses play in contributing to the State’s economic and job growth. Emergent is proud to be amongst the technology and life sciences companies that have chosen Maryland as its home.”

The criteria for the Biotechnology Firm of the Year Award include: achieving significant and measurable success, contributing to the advancement of biosciences through cutting-edge research and development, crisply executing a growth strategy, and helping foster a vibrant biotech community.

TCM is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM’s mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Nomination Deadline Approaching for 2010 El-Hibri Peace Education Prize

The El-Hibri Peace Education Prize is awarded yearly to an individual or organization who is making valuable contributions to peace education and social justice in the Middle East. The purpose of the $10,000 prize is to recognize outstanding peace educators, to provide financial support to continue peace education and study, and to promote the importance of peace education globally by affirming efforts to integrate peacemaking into curricula at all levels of education.

The nomination period for the 2010 prize ends June 6th. This year’s winner will be announced July 11, 2010 and the award will be presented on September 21, 2010, the International Day of Peace. Nominees can be individuals or organizations, but they must be based in the United States and be making valuable contributions to the theory, practice, and teaching of peace and social justice in the Middle East. More information about the nomination process and the prize itself can be found at http://www.elhibriprize.org .

Fuad El-Hibri, Founder of the El-Hibri Peace Education Prize and Dr. Abdul Aziz Said, First Laureate of the El-Hibri Peace Education Prize

The prize was founded in 2007 by businessman and philanthropist Fuad El-Hibri and his wife Nancy El-Hibri in order to highlight the importance of peace education and to support people who are working for a just, peaceful and healthy planet. El-Hibri is the CEO of Emergent BioSolutions, as well Chairman of the El-Hibri Charitable Foundation. Past winners include Professor Abdul Aziz Said (2007); Scott Kennedy (2008) ; and Dr. Mary Elizabeth King (2009).

For more information, contact: nonviolence@igc.org

Emergent BioSolutions to Participate in June 2010 Investor ConferencesEmergent BioSolutions to Participate in June 2010 Investor Conferences

Fuad El-Hibri, CEO of Emergent BioSolutions Inc., announces that the company will be participating in the following investor conferences during June 2010:

• The Jefferies & Company 2010 Global Life Sciences Conference
  New York, NY.
  June 8, 2010
  Corporate Overview Presentation
  11:00 AM Eastern
  There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

• The Needham & Company 9^th Annual Healthcare Conference
  New York, NY.
  June 10, 2010
  Corporate Overview Presentation
  3:20 PM Eastern
  There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.

Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments

ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax^® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company’s international sales efforts have resulted in these sales of an undisclosed number of BioThrax doses for aggregate revenue of approximately $2.3 million in the second quarter.

“Emergent recognizes that governments play a key role in protecting citizens against the growing threat of bioterrorism,” said Allen Shofe, senior vice president public affairs of Emergent BioSolutions. “As the maker of the only U.S. FDA-licensed anthrax vaccine, and in line with our corporate mission to protect life, we are honored to support such biopreparedness efforts of allied international governments.”

About BioThrax

BioThrax is the only U.S. FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. Since 1998, the U.S. government has procured over 42 million doses of BioThrax. During that time period, more than 9.5 million doses have been administered to nearly 2.4 million military personnel. For full prescribing information, please visit www.biothrax.com/prescribinginformation_biothrax_us.pdf.

Important Safety Information for BioThrax^®

The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema and arm motion limitation. The most common (>5%) systemic adverse reactions were muscle aches, fatigue and headache. Serious allergic reactions, including anaphylactic shock, have been observed during post-marketing surveillance in individuals receiving BioThrax.

Pregnant women should not be vaccinated unless the potential benefits of vaccination have been determined to outweigh the potential risk to the fetus. If BioThrax is used during pregnancy, or if the patient becomes pregnant during the immunization series, the patient should be apprised of the potential hazard to the fetus. This product should be administered with caution to persons with a possible history of latex sensitivity since the vial stopper contains dry natural rubber.

Vaccination with BioThrax should be avoided by individuals with a history of anaphylactic or anaphylactic-like reaction following a previous dose of BioThrax.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2010, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax^® procurement; our ability to obtain new BioThrax^® sales contracts; our plans to pursue label expansions and improvements for BioThrax^®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation

Fuad El-Hibri

The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.

BARDA canceled the RFP for the procurement for rPA vaccines after a technical evaluation panel determined that no proposals submitted by vaccine developers could meet the ProjectBioShield statutory requirement of having the product ready for licensure within eight years.

An amendment issued by BARDA to BAA 09-34 at the same time, however, enable companies to submit proposals to obtain development funding for rPA vaccine candidates, which Emergent has been strongly encouraged to do by BARDA.

Emergent plans to submit its proposal to the BAA by the end of this year, in front of the due date of February 1, 2010 for the proposals.

This announcement also does not impact Emergent’s $400 million procurement with the Centers for Disease Control and Prevention to manufacture and deliver 14.5 million doses of BioThrax for the Strategic National Stockpile.

“With this action, BioThrax remains a critical and long-term countermeasure for the US government,” Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, said. “In addition, based upon encouragement by the USG, we believe our rPA vaccine is well-positioned to obtain a development contract under this BAA. Our anthrax franchise solidifies Emergent as a leader in the development and supply of anthrax medical countermeasures.”

BioThrax is currently being delivered under this contract with an expected completion of deliveries by September 2011. BioThrax is the only FDA licensed vaccine for the prevention of anthrax diseases.

“We believe that BioThrax will remain a premier product based on its recent enhancements, such as four-year dating, a reduced vaccination schedule and intramuscular route of administration, together with the potential for a further reduction in the vaccination schedule to a 3-dose primary series with a 3-year boost,” Daniel J.Abdun-Nabi, president and chief operating officer of Emergent BioSolutions, said. “BioThrax continues to be the product of choice for the USG and other customers seeking to address the anthrax threat.”

BARDA and Emergent are also in separate talks for a contract that would see BARDAA fund scale-up and related activities to obtain FDA licensure for large-scale production of BioThrax at Emergent’s new 50,000-square-foot Lansing, Mich., manufacturing facility.

“I am proud that Lansing remains home to America’s first line of defense against what experts say is the single biggest bioterror threat, anthrax,” U.S. Rep. Mike Rogers, MI-08, said. “The good news about the cancellation of this particular proposal is HHS recommitted itself to the Lansing-made anthrax vaccine and has opened a new proposal for a next-generation anthrax vaccine for which Emergent has indicated it will compete.

“Rest assured, I will continue working to strengthen our nation’s existing bioterror preparedness measures and protect national security jobs in Lansing.”